Abstract:Background: Cholangiocarcinoma (CCA) is a malignancy of the bile duct epithelium that is commonly found in the Thai population. CCA has poor prognosis and a low survival rate due to the lack of early diagnosis methods and the limited effectiveness of current treatments. A number of oncogenic spliced-transcripts resulting from mRNA splicing errors have been reported in CCA, and aberrant mRNA splicing is suspected to be a key driver of this cancer type. The hyperphosphorylation of serine/arginine rich-splicing factors (SRSFs) by serine/arginine protein kinases (SRPKs) causes them to translocate to the nucleus where they facilitate gene splicing errors that generate cancer-related mRNA/protein isoforms. Methods: The correlation between SRPK expression and the survival of CCA patients was analyzed using data from The Cancer Genome Atlas (TCGA) dataset. The effect of SRPK inhibitors (SRPIN340 and SPHINX31) on two CCA cell lines (KKU-213A and TFK-1) was also investigated. The induction of cell death was studied by Calcein-AM/PI staining, AnnexinV/7AAD staining, immunofluorescence (IF), and Western blotting (WB). The phosphorylation and nuclear translocation of SRSFs was tracked by WB and IF, and the repair of splicing errors was examined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Results: High levels of SRPK1 and SRPK2 transcripts, and in particular SRPK1, correlated with shorter survival in CCA patients. SRPIN340 and SPHINX31 increased the number of dead and apoptotic cells in a dose-dependent manner. CCA also showed diffuse expression of cytoplasmic cytochrome C and upregulation of cleaved caspase-3. Moreover, SRSFs showed low levels of phosphorylation, resulting in the accumulation of cytoplasmic SRSF1. To link these phenotypes with aberrant gene splicing, the apoptosis-associated genes Bridging Integrator 1 (BIN1), Myeloid cell leukemia factor 1 (MCL-1) and B-cell lymphoma 2 (BCL2) were selected for further investigation. Treatment with SRPIN340 and SPHINX31 decreased anti-apoptotic BIN1+12A and increased pro-apoptotic MCL-1S and BCL-xS. Conclusions: The SRPK inhibitors SRPIN340 and SPHINX31 can suppress the phosphorylation of SRSFs and their nuclear translocation, thereby producing BIN1, MCL-1 and BCL2 isoforms that favor apoptosis and facilitate CCA cell death.

Identification of Sphk1 As A Therapeutic Target and Marker of Poor Prognosis in Cholangiocarcinoma

Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.

The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma

Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis

Overexpressions of Ck2 Beta and Xiap Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Identification of Chondroitin Polymerizing Factor (CHPF) As Tumor Promotor in Cholangiocarcinoma Through Regulating Cell Proliferation, Cell Apoptosis and Cell Migration

SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1, MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells

Overexpressions of CK2β and XIAP Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

SPHK1 Promotes HNSCC Immune Evasion by Regulating the MMP1-PD-L1 Axis

Antitumor Activity of the Combination of an Hsp90 Inhibitor and A Pi3k/Mtor Dual Inhibitor Against Cholangiocarcinoma

Cancer Therapy : Preclinical Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI 3 K / Akt / NFk B Pathway in Human Non – Small Cell Lung Cancer

Molecular profiling reveals potential targets in cholangiocarcinoma

CHK1 Targets Spleen Tyrosine Kinase (L) for Proteolysis in Hepatocellular Carcinoma

Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment

Gene Expression‐based Chemical Genomics Identifies Heat‐shock Protein 90 Inhibitors As Potential Therapeutic Drugs in Cholangiocarcinoma

Antitumor Effect of the Novel Sphingosine Kinase 2 Inhibitor ABC294640 is Enhanced by Inhibition of Autophagy and by Sorafenib in Human Cholangiocarcinoma Cells.

Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypes

Targeting PDGF-CC As a Promising Therapeutic Strategy to Inhibit Cholangiocarcinoma Progression

Screening and Identification of Genes Associated with Cell Proliferation in Cholangiocarcinoma.

Transcriptomic Analysis and Identification of Prognostic Biomarkers in Cholangiocarcinoma

Sphingosine Kinase 1 is Associated with Gastric Cancer Progression and Poor Survival of Patients